NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors

Haematologica. 2016 Apr;101(4):e133-4. doi: 10.3324/haematol.2015.136499. Epub 2015 Dec 17.
No abstract available

Keywords: B-cell precursor acute lymphoblastic leukemia; BCR-ABL1-like; adolescents; tyrosine kinase inhibitors.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Bone Marrow Transplantation*
  • Female
  • Gene Expression
  • Humans
  • Nuclear Pore Complex Proteins / genetics*
  • Nuclear Pore Complex Proteins / metabolism
  • Oncogene Proteins, Fusion
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins c-abl / genetics*
  • Proto-Oncogene Proteins c-abl / metabolism
  • Recurrence
  • Remission Induction
  • Transplantation, Isogeneic
  • Treatment Failure

Substances

  • NUP214 protein, human
  • Nuclear Pore Complex Proteins
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-abl